

REFERENCES

- **Abdullah F, Zhang Y, Camp M, Rossberg MI, Bathurst MA, Colombani PM, et al (2009):** Splenectomy in hereditary spherocytosis: Review of 1,657 patients and application of the pediatric quality indicators. *Pediatr Blood Cancer*. Jul ;52(7):834-7. [Medline].
- **Adamkiewicz TV, Sarnaik S, Buchanan GR, Iyer RV, Miller ST, Pegelow CH, Rogers ZR, Vichinsky E, Elliott J, Facklam RR, O'Brien KL, Schwartz B, Van Beneden CA (2003) :** Invasive pneumococcal infections in children with sickle cell disease in the era of penicillin prophylaxis, antibiotic resistance, and 23-valent pneumococcal polysaccharide vaccination. *J Pediatr*. 2003; 143: 438–44. [PubMed]
- **Adamkiewicz TV, Abboud MR, Paley C, et al. 2009** Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are associated with iron load and liver injury. *Blood* ;114(21):4632-4638.
- **Adams RJ, Brambilla D.(2005)** Optimizing Primary Stroke Prevention in Sickle Cell Anemia Trial Investigators; Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease. *N Engl J Med.*; 353: 2769–78.
- **Aessopos A, Farmakis D and Loukopoulos D. (2002):** Elastic tissue abnormalities resembling pseudoxanthoma elasticum in beta thalassemia and the sickling syndromes. *Blood*; 99(1):30-35.
- **Aessopos A., Farmakis D., Deftereos S., Tsironi M., Tassipules S., Moyssakis I. And Karagiorga M. (2004):** Thalassemic heart disease

a comparative evaluation of thalassemia major and thalassemia intermedia, *Chest*; 127(50): 1523-30

- **Al –Salem A.H., Naserullah Z.,Qaisaruddin S., et al (2002) :** splenectomy for hematological disease:The Qatif Central Hospital experience.*Ann Saudi Med*; 19 (4): 325-330.
- **Al-Ali, AK (1996).** "Common G6PD variant from Saudi population and its prevalence" (PDF). *Annals of Saudi Medicine* 16 (6): 654–6. ISSN 02564947. PMID 17429252.
- **Aldudak B, Karabay Bayazit, Noyan A, Ozel A, Anarat A, Sasmaz I, Kiline Y, Gali E, Arnart R and Dikmen N., (2000):** Renal function in pediatric patients with thalassemia major. *Pediatr Nephrol*, 15(1-2): 109-112.
- **Aliyu ZY, Kato GJ, Taylor J, Babadoko A, Mamman AI, Gordeuk VR, Gladwin MT. (2008)** Sickle cell disease and pulmonary hypertension in Africa: a global perspective and review of epidemiology, pathophysiology, and management. *Am J Hematol*. 2008; 83: 63–70.
- **Al-Saqladi AW, Bin-Gadeen HA, Brabin BJ (2010):** Faculty of Medicine & Health Sciences, Aden University, Yemen.
- **Alter, B.P. (2003):** Orkin SH, Nathan DG. The Thalassemias. In: Nathan and Oski's Hematology of Infancy and Childhood, 6th ed, Nathan, DG, Orkin, SH, Ginsberg, D, Look, AT (Eds), WB Saunders, Philadelphia 2003. p. 842.
- **Andrews, David F., Freedman, Melvin H., Bronsiegel-Weintrob, Naomi, Olivieri, Nancy F., Tyler, Beverley, Holland, F. John (2007)** Measurement, Complications and side effects,

Demographic aspects, Growth, Growth (Physiology), Ferritin, Chelation therapy in beta thalassemia., The New England Journal of Medicine, ISSN: 0028-4793.

- **Angastiniotis M, Pavlides N, Aristidou K. (1998):** Bone pain in thalassemia; assessment of DEXA and MRI findings. J Pediatr Endocrinol Metab; 11 [suppl 3]; 799-784.
- **Arabi B, Haghshenas M and Rakeii V. (1998):** Visual failure caused by suprasellar extramedullary hematopoiesis in beta thalassemia; case report. Neurosurgery; 42(4); 922-925.
- **Ataga KI, Moore CG, Jones S, Olajide O, Strayhorn D, Hinderliter A, Orringer EP. (2006)** Pulmonary hypertension in patients with sickle cell disease: a longitudinal study. Br J Haematol. 2006; 134: 109–15.
- **Atichartakan V., Likittanasombat K., Chuncharunee S. Chandanamattha P., Worapongpaiboon S.and Aryuarachia K. (2003):** Pulmonary arterial hypertension in previously splenectomized patients with beta thalassemic disorders. Int J. Hematol.; 78(2):139-145.
- **Austin H, Key NS, Benson JM, Lally C, Dowling NF, Whitsett C, Hooper WC.(2007)** Sickle cell trait and the risk of venous thromboembolism among blacks. Blood. 2007; 110: 908–12.
- **Bakanay SM, Dainer E, Clair B, Adekile A, Daitch L, Wells L, Holley L, Smith D, Kutlar A. (2005)** Mortality in sickle cell patients on hydroxyurea therapy. Blood. 2005; 105: 545–7.
- **Ballas SK (1997):** management of sickle pain . curr opin hematol. Mar;4(2):104-11. .(medline).

- **Barragan E., Bolufer P., Prieto F., (2006):** Molecular detection of Spanish delta beta thalassemia during prenatal diagnosis. Clin Chim Acta; 368: 195-8.
- **Barton JC. (2007):** Drug evaluation: Deferritin for iron overload disorders. J Drug; 10(7):480-90.
- **Bernard G. Forget (2000):** Thalassemia syndromes. In Roland H., Edward J., Bruce F., Harvey J., Leslie E. and Philip M. (Eds): Hematology Basic Principles and Practice, 3rd edition. Churchill Livingstone, New York, pp., 485-510.
- **Beutler E (2008).** "Glucose-6-phosphate dehydrogenase deficiency: a historical perspective". Blood 111 (1): 16–24. doi:10.1182/blood-2007-04-077412. PMID 18156501
- **Beutler E., Hoffbrand AV. and Cook JD. (2003):** Iron deficiency and overload. Hematology Am. Soc. Hematol. Educ. Program; 40-61. y; (1): 42 – 47
- **Bhatia M, Walters MC. (2008)** Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future. Bone Marrow Transplant. 2008; 41: 109–17. [PubMed]
- **Bolton-Maggs PH, Stevens RF, Dodd NJ, Lamont G, Tittensor P, King MJ (August 2004).** "Guidelines for the diagnosis and management of hereditary spherocytosis". Br. J. Haematol. 126 (4): 455–74. doi:10.1111/j.1365-2141.2004.05052.x. PMID 15287938
- **Bookchin RM, Iew vl. (1996) :** Pathophysiology of sickle cell anemia. Hematol oncolclinnortham. 10(6):1241-53. .(medline).
- **Borgna-pignatti C, Carnelli V and Caruso V. (1998):** Thromboembolic events in beta thalassemia major; an Italian

multicenter study. *Acta haematol*; 99:76-79.

- **Brawley OW, Cornelius LJ, Edwards LR, Gamble VN, Green BL, Inturrisi C, James AH, Laraque D, Mendez M, Montoya CJ, Pollock BH (2008)** National Institutes of Health Consensus Development Conference statement: hydroxyurea treatment for sickle cell disease. *Ann Intern Med*. 2008; 148: 932–8. [PubMed]
- **Bunn HF.(1997):** pathogenesis and treatment of sickle cell disease. *n engl j med*. 11:337(11):762-9.(medline).
- **Cappellini MD, Cohen A, Piga A,(2006)** A phase 3 study of deferasirox (ICL670), a once-daily oral iron chelator, in patients with β -thalassemia. *Blood*. 2006;107(9):3455-3462.
- **Cappellini MD, Fiorelli G (2008).** "Glucose-6-phosphate dehydrogenase deficiency". *Lancet* 371 (9606): 64–74. doi:10.1016/S0140-6736(08)60073-2. PMID 18177777
- **Caterina BP and Renzo G (2004):** Thalassemias and related disorders: Quantitative disorders of hemoglobin Synthesis. In: Wintrobe's clinical hematology. Greer JP, Foester J., Lukens JN, Rodgers GM, Paraskevas F, Glader B(eds). Lippincott Williams& Wilkins, pp 1052-1075.
- **Cazzola M., Bornga Pignattic and Locatelli F., (1997):** A moderate transfusion regimen may reduce iron loading in β thalassemia major without producing excessive expansion of erythropoiesis. *Transfusion*, 37:135-40.
- **Chao TH and Wang B (1996):** The correlation of serum ferritin to Ca/P metabolism and bone density study in thalassemic patients. *J Pediatr Endocrinol Metab*; 9(6): 809-4.

- **Cianciulli P, Sorrentino F and Maffei L. (2002):** Cardiovascular involvement in thalassemic patients with pseudoxanthoma elasticum-like skin lesions. A long term follow up study. *Eur J Clin invest*; 32: 700-706.
- **Clarke GM. and Higgins TN. (2000):** Laboratory investigation of hemoglobinopathies and thalassemias review and up date. *Clin. Chem.*; 46: 1284-90.
- **Cohen AR (2006):** New Advances in Iron Chelation Therapy. *Hematology*; (1): 42 - 47.
- **Cohen AR., Galanello R., Pennell DJ., Cunningham MJ., Vichinsky E. (2004):** Thalassemia. In: *Hematology*. Washington, DC: American Society of Hematology; 14-34.
- **Cooley, G.B. and Lee, P. (1925):** A series of cases of splenomegaly in children with anemia and peculiar bone Changes. *Trans. Am. Pediatr. Soc.*, 37:29.
- **Cotran, Ramzi S.; Kumar, Vinay; Fausto, Nelson; Nelso Fausto; Robbins, Stanley L.; Abbas, Abul K. (2005).** Robbins and Cotran pathologic basis of disease. St. Louis, Mo: Elsevier Saunders. pp. 625. ISBN 0-7216-0187-1.
- **Di Naro Ghezzi F and Vitucci A. (2007):** prenatal diagnosis of b-thalassemia using fetal erythroblasts enriched from maternal blood by a novel gradient. *Hum Repord*; 6:571-4.
- **Dubey A.P., Sudha S., Parakh A. (2007):** Deferasirox: The New Oral Iron Chelator. *Indian Pediatric*;(44) 603-607

- **Duncan GW. (1997):** Ischemic stroke in sickle cell disease : a review. Tenn med. 90(12):498-9 (medline)
- **Eber S, Lux SE (April 2004).** "Hereditary spherocytosis--defects in proteins that connect the membrane skeleton to the lipid bilayer". Semin. Hematol. 41 (2): 118–41.
- **Edward, J. Benz, Jr. Patricia J. V. (1995):** Thalassemia syndrome: Blood diseases of infancy and childhood textbook, seventh edition Philadelphia Sydney Tokyo Toronto, 460-491.
- **Ehlers, K.H.; Giardina, P.J. and Lesser, M.L. (1991):** Prolonged survival in patient with beta thalassemia major treated with desferrioxamine. J. Pediatric; 118:54-545.
- **El-Alfy M.S. and El-Sayed M.H (2004):** Over whilming post splenectomy infection: Is quality of patient knowledge enough for prevention? Haematol 5(1): 77-80.
- **El-Beshlawy A. (2005):** The Egyptian experience with oral iron chelators. Hematology, Volume 10, pp. 174-175(2).
- **Eldor A., Durst, R , Hy Am E., Goldfarb A., Gillis S., Rachmilewitz E. A., Abramov A., MacLouf J., Godefray Y C, De Raucourt E. and Guillin M. C. (1999):** A chronic hypercoagulable state in patients with beta thalassemia major is already present in childhood. Br. J. Hematol; 107(4): 739-46.
- **Eshghi P, Alavi S, Ghavami S, Rashidi A.(2007)** Growth impairment in beta-thalassemia major: the role of trace element deficiency and other potential factors. J Pediatr Hematol Oncol. 29(1):5-8.

- ***Evangelia Yannaki George Stamatoyannopoulos (2010)***
Hematopoietic stem cell mobilization strategies for gene therapy of beta thalassemia and sickle cell disease New York Academy of Sciences DOI: 10.1111/j.1749-6632.2010.05576.x
- ***Fibach E, Prasanna P, Rodgres GP, Samid D (1993):*** Enhanced fetal hemoglobin production by phenylacetate and 4-phenyl butyrate In erythroid precursors derived from normal blood donors and β -thalassemia. Blood ; 82: 2203.
- ***Forget BG, (2000):*** Thalassemia syndromes in: Hematology: Basic principles and practice; 3rd ed, Hoffman, R, Benz EJ Jr, Shattil, SJ, et al (Eds), Churchill Livingstone, New York, 2000, p. 458-509
- ***Forget BG. (2001):*** Molecular genetics of the human globin genes. In: Steinberg MH, Forget BG, Higgs DR, Nigel RL, eds. Disorders of haemoglobin. Cambridge: Cambridge University Press: 117-130.
- ***Frank JE (2005).*** "Diagnosis and management of G6PD deficiency". Am Fam Physician 72 (7): 1277–82. PMID 16225031.
- ***Fucharaen S, Siritanaratkul N, Winichagoon P, Siriboon W, Chowathaworn J, (1993):*** Hydroxyurea increases HbF levels and improves the effectiveness of erythropoiesis in β -thalassemia Hb E disease. Blood; 82:357a.
- ***Fucharoen M and Winichagoon P. (2000):*** Clinical and hematologic aspects of hemoglobin E beta-thalassemia. Curr opin Hemat; 7:106-112.

- **Galanello R, Paris S and Barella S. (2001):** Cholelithiasis and Gilbert syndrome in homozygous β -thalassemia. *Br J Hamatol*; 115:026-928.
- **Gallagher PG, Forget BG (December 1998).** "Hematologically important mutations: spectrin and ankyrin variants in hereditary spherocytosis". *Blood Cells Mol. Dis.* 24 (4): 539–43.
- **Ganz T. (2003):** Hepcidin, a key regulator of iron metabolism and modulator of inflammation. *Blood*; 102: 783-8.
- **Gaston MH, Verter JI, Woods G, Pegelow C, Kelleher J, Presbury G, Zarkowsky H, Vichinsky E, Iyer R. et al. (1986)** Prophylaxis with oral penicillin in children with sickle cell anemia. A randomized trial. *N Engl J Med.* 1986; 314: 1593–9.
- **Gladwin MT, Rodgers GP. (2000)** Pathogenesis and treatment of acute chest syndrome of sickle-cell anaemia. *Lancet.* 2000; 355: 1476–8.
- **Gladwin MT, Schechter AN. (2004) :** (Nitric oxide therapy in sickle cell disease. *Semin Hematol.* 2001; 38: 333–42.
- **Goljan. (2010).** Rapid Review Pathology. Page 213.
- **Goussetis E, Perisreri J, Kitra V, Kattamis A, Petropoulos D, Papassotiriou L, Garphakos S (2000):** Combined umbilical cord blood and bone marrow transplantation in the treatment of beta thalassemia major. *Pediatr. Hematol Oncol*; 17 (4): 307-14.
- **Grace RF, Mednick RE, Neufeld EJ. (2009)** Compliance with immunizations in splenectomized individuals with hereditary spherocytosis. *Pediatr Blood Cancer.* Jul ;52(7):865-7. [Medline]

- **Grundy R G, Woods K A, Savage M O, Evans J P. (1994):** Relationship of endocrinopathy to iron chelation status in young patients with thalassaemia major. *Arch Dis Child*; 71: 128-132.

- **Hamilton JW, Jones FG, McMullin MF (2004).** "Glucose-6-phosphate dehydrogenase Guadalajara--a case of chronic non-spherocytic haemolytic anaemia responding to splenectomy and the role of splenectomy in this disorder". *Hematology* 9 (4): 307–9.

- **Hassan M, Hasan S, Giday S, Alamgir L et al 2003.**Hepatitis C virus in sickle cell disease ,Division of Gastroenterology, Howard University Hospital, Washington, DC, USA95(10):939-42

- **Hassanshahi G, Arababadi MK, Assar S, Hakimi H, Karimabad MN, Abedinzadeh M, Rafatpanah H, Derakhshan R 2011.** Molecular Medicine Research Center, Rafsanjan University of Medical Sciences, Rafsanjan, Iran. *Arch Virol.* 2011 Jul;156(7):1111-5..

- **Hayward A, Ambruso D, Battaglia F, Donlon T, Eddelman K, Giler R, Hobbins J, Hsia Y.E, Quinones R, Shpall E, Trachtenberg E, Giardina P. (1998):** Michrochimerism and tolerance following intrauterine transplantation and transfusion for alpha-thalassemia-1. *Fetal Diagn Ther*; 13:8-14.

- **Hemolytic Anemia: Overview - eMedicine Hematology".**
<http://emedicine.medscape.com/article/201066-overview>.
 Retrieved 2009-02-07

- **Hoffbrand AV. Grady RW. Berdouka S. (1998):** Iron chelation: combined therapy could be a better approach. *Blood*, 92(2):16b.

- **Honig GR (2000):** Hemoglobin disorders in: Nelson textbook of pediatrics. Behrman RE, kliegman RM and Jenson HB (eds). Sixteenth edition WB Saunders Company. Philadelphia, London Toronto, Montreal Sydney, Tokyo, p 1478.
- **Honig, G.R. (2004):** Hemoglobin disorders, in Nelson textbook of pediatrics. By Behrman, R.E, kliegman R.M. & Jenson S.O. 17th ed. P. 1630-1634.
- **Hussein IR, Temtamy SA, El-Beshlawy A. (1993):** Molecular characterization of beta-thalassemia in Egyptians. Hum Mutat; 2:48-52.
- **IKutter, D. and Thoma, J. (2006)** 'Hereditary spherocytosis and other hemolytic anomalies distort diabetic control by glycated hemoglobin', Clinical Laboratory, 52(9-10), 477-481.
- **Issaragrisil, S. (2002):** Stem cell transplantation for thalassemia Int. J. Hematol. 1 (76 Supply):307-9.
- **Jose RL, Batubara (2004)** Delayed puberty in thalassemia major. Paediatrica Indonesiana, Vol. 44 No. 7-8 •
- **Kaplan M, Hammerman C. (2004)** Glucose-6-phosphate dehydrogenase deficiency: a hidden risk for kernicterus. *Semin Perinatol.* ;28(5):356-64. [Medline].
- **Kato GJ, Gladwin MT, Steinberg MH. (2007):** Deconstructing sickle cell disease: reappraisal of the role of hemolysis in the development of clinical subphenotypes. Blood Rev. 2007; 21: 37–47. [PubMed]

- **Kattamis CA and Kattamis AC.):** Management of thalassemia: growth and development, hormone substitution, vitamin supplementation, vaccination. *Semin Hematol*; 32:269-279.
- **Kazazinan HH (1990):** The thalassemia syndromes, molecular basis and prenatal diagnosis. *Semin Hematol*; 27:209-11.
- **Kearney SL, Nemeth E, Neufeld EJ, Thapa D, Ganz T, David A. Weinstein, Melody J. Cunningham (2007):** Urinary hippuric acid in congenital chronic anemias. *Pediatr Blood Cancer*; 48:57-63.
- **Khalifa A.S; Sallam T; Tawfeek Z; (1990):** Effect of splenectomy on platelet function in β -thalassemia. *Egypt J. Pediatr.*, 7(1-2): 201.
- **Khalifa AS, Baffico M, Heshmat NM, (1995):** Relationship between the hematological phenotype and the type of beta-thalassemia mutation in Egyptian children. *Egypt J Hematol*; 20(2): 130-137.
- **Khalifa AS, Salem M, Mounir E, El-Tawil MM, El-Sawy M, Abd Al-Aziz MM. (2004):** Abnormal glucose tolerance in Egyptian beta thalassemic patients: Possible association with genotyping. *Pediatr Diabetes*; 5: 126-132.
- **Khalifa, A.S.; Abdel Fattah, S.A.; El-Sokkary, S. et al. (1982):** Thyroid functions in β α -thalassemia major Egyptian children. *Egypt. J. Hematol.*, 7(12): 65-76.
- **Khong PL, Chan GC, Lee SL, Au WY, Fong DY, Tsang KW, Ooi GC. (2003):** Thin section CT features and correlation with pulmonary function and iron overload in beta-thalassemia. *Radiology*; 229(2):507-512.

- **Kolb S, Vranckx R, Huisse MG, Michel JB, Meilhac O (July 2007).** "The phosphatidylserine receptor mediates phagocytosis by vascular smooth muscle cells". *The Journal of Pathology* 212 (3): 249–59. doi:10.1002/path.2190. PMID 17534843
- **Koshy M, Dorn L, Bressler L,(2000):**2-Deoxy-azacytidine (Decitabine) and fetal hemoglobin induction in sickle cell anemia. *Blood* 2000; 96:2379-2384
- **Krishnamurti L, Abel S, Maiers M, Flesch S. (2003):** Availability of unrelated donors for hematopoietic stem cell transplantation for hemoglobinopathies. *Bone Marrow Transplant.* 2003; 31: 547–50.
- **Kumar P, Clark M (2005),** *Clinical Medicine* 6th Ed, Elsevier Saunders pg 437
- **Kushner JP, Porter JP, Olivieri NF(2001).** Secondary iron overload. *Hematology Am Soc Hematol Educ Program.*; 2001: 47–61. [PubMed]
- **Kwiatkowski DP.(2005):** "How malaria has affected the human genome and what human genetics can teach us about malaria". *Am. J. Hum. Genet.* 77 (2): 171–92.
- **Kwiatkowski JL (2008):** Oral iron chelator. *Pediatr Clin N Am* 55: 461-482.
- **Low, L.C.K. (1997):** Growth, puberty and endocrine function in β^0 thalassemia major. *J Pediatric Endocrinol Metab.*, 10:175-184.
- **Lukens, T.N. (1993):** The thalassemia and related disorders. In: *Wintrobe's clinical hematology*. 9th edition. Lee GR.; Bithell TC;

Foerster J; Athens JW; Lukens J.N. (eds). Lea and Febiger; Philadelphia PA, 1:1102-45.

- **Machado RF, Anthi A, Steinberg MH, Bonds D, Sachdev V, Kato GJ, Taveira-DaSilva AM, Ballas SK, Blackwelder W, Xu X, Hunter L, Barton B, Waclawiw M, Castro O, Gladwin MT, (2006):** MSH Investigators. N-terminal pro-brain natriuretic peptide levels and risk of death in sickle cell disease. JAMA. 2006; 296: 310–8. [PubMed]
- **Magro, S., Puzzonia, P., Consarino, C. et al. (1990):** Hypothyroidism in patient with thalassemia. Acta Hematol; 84:72-76.
- **Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. (2000):** Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 2000; 95: 78–82. [PubMed]
- **Masera G, Jean G, Conter V, Terzoli S, Mauri RA, Cazzaniga M. (1980):** Sequential study of liver biopsy in thalassemia. Arch Dis Child; 55: 800-802.
- **Mazza, Joseph (2001).** Manual of Clinical Hematology. Lippincott Williams & Wilkins. pp. 101–2. ISBN 0781729807.
- **Mc Cormack MK, Dicker L, Katz SH, et al (1976).** Growth pattern of children with sickle cell disease. Hum Biol;48:429-37.
- **Mc Donagh KT and Neinhuis AW (1993):** The thalassemias. In: Hematology of infancy and childhood. 4th ed., Nathan DG and Oski FA (eds) WB Saunders Company, Philadelphia P. 783.

- **McLeod C, Fleeman N, Kirkham J, (2009):** (: Deferasirox for the treatment of iron overload associated with regular blood transfusions (transfusional haemosiderosis) in patients suffering with chronic anemia: a systematic review and economic evaluation. *Health Technol Assess.* 13(1): iii-iv, ix-xi, 1-121

- **Mehta A, Mason PJ, Vulliamy TJ (2000).** "Glucose-6-phosphate dehydrogenase deficiency". *Baillieres Best Pract. Res. Clin. Haematol.* 13 (1): 21–38. PMID 10916676.

- **Miller ST, Sleeper LA, Pegelow CH, Enos LE, Wang WC, Weiner SJ, Wethers DL, Smith J, Kinney TR. (2000):** Prediction of adverse outcomes in children with sickle cell disease. *N Engl J Med.*; 342: 839.

- **Miller ST, Wright E, Abboud M, Berman B, Files B, Scher CD, Styles L, Adams RJ. (2001):** STOP Investigators; Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia. *J Pediatr.*; 139: 785–9. [PubMed]

- **Mitchell BL. (2007):** Sickle cell trait and sudden death--bringing it home. *J Natl Med Assoc.* 2007; 99: 300–5. [PubMed]

- **Modell B. Berdoukas V. (1984):** In: clinical approach to thalassemia. Grune and Stratton (eds). W.B. Saunders Company, Hartcourt brace Jovanovich publishers, p. 10.

- **Monga A, Makkar RP, Arora A, Mukhopadhyay S, Gupta AK (2003).** "Case report: Acute hepatitis E infection with coexistent glucose-6-phosphate dehydrogenase deficiency". *Can J Infect Dis* 14 (4): 230–1. PMID 18159462

- **Morris C, Vichinsky E, Styles L. (1999):** Clinician assessment for acute chest syndrome in febrile patients with sickle cell disease: is it accurate enough? *Ann Emerg Med.* 1999; 34: 64–9. [PubMed]
- **Nkhoma ET, Poole C, Vannappagari V, et al. (2009)** The global prevalence of glucose-6-phosphate dehydrogenase deficiency: a systematic review and meta-analysis. *Blood Cells Mol Dis.* ;42(3):267-78.
- **Ohene- frembonge K, smith-whitley k(1997):** use of hydroxyurea in children with sickle cell disease : what comes next ? *semin hematol*; 34
- **Ohene - Frempong K, Steinberg MH(2001),.** *Clinical aspects of sickle cell anemia in adults and children.* In: *Steinberg MH, Forget BG, Higgs DR, Nagel RL* editors, *Disorders of Hemoglobin*, 1st Ed. USA: Cambridge University Press;2001 .pp.611-70
- **Olivieri N.F, Brittenham GM, Matsui D. (1995):** Iron chelation therapy with oral deferiprone in patients with thalassemia major N. *Engl. J. Med*; 332: 912.
- **Olivieri NF, and Brittenham GM (2007):** Iron chelating therapy and the treatment of thalassemia. *Blood* 2007; 1; 89(3):739-761.
- **Olivieri NF, Nathan DG and Macmillan JH (1994):** Survival in medically treated patients of Beta thalassemia N. *Engl. J. Med*; 331: 574-578.
- **Overturf GD. (1999)** Infections and immunizations of children with sickle cell disease. *Adv bediatr infect dis*; 14: 191-2180(medline)
- **Paik CH, Alavi I, Dunea G, Weiner L. (1970):** Thalassemia and gouty arthritis. *JAMA*; 213:296-297.

- ***Palmieri L, Ronca F, Malengo S and Bertelli A (1994):*** Protection of beta-thalassaemic erythrocytes from oxidative stress by propionyl carnitine. *Int. J. Tissue React*; 16(3): 121-129.
- ***Panepinto JA, Walters MC, Carreras J, Marsh J, Bredeson CN, Gale RP, Hale GA, Horan J, Hows JM, Klein JP, Pasquini R, Roberts I, Sullivan K, Eapen M, Ferster A. (2007):*** Non-Malignant Marrow Disorders Working Committee, Center for International Blood and Marrow Transplant Research; Matched-related donor transplantation for sickle cell disease: report from the Center for International Blood and Transplant Research. *Br J Haematol.*; 137: 479–85.
- ***Pantelakis S and Rodda CR (1994):*** Endocrine aspects of thalassemia major. *Acta Paediatr; Suppl* 406: 105-6.
- ***Paul Schick, (2009):*** emedicine. medscape.com /article /201066-overview Apr 27, 2009.
- ***Pegelow CH, Macklin EA, Moser FG, Wang WC, Bello JA, Miller ST, Vichinsky EP, DeBaun MR, Guarini L, Zimmerman RA, Younkin DP, Gallagher DM, Kinney TR. (2002):*** Longitudinal changes in brain magnetic resonance imaging findings in children with sickle cell disease. *Blood.*; 99: 3014–8.
- ***Perrotta S, Gallagher PG, Mohandas N (2008).*** "Hereditary spherocytosis". *Lancet* 372 (9647): 1411–26. doi:10.1016/S0140-6736(08)61588-3.
- ***Piga A, Gagliot C, Fogliacco E and Tricta F. (2003):*** comparative effects of deperiprone and deferoxamine on survival and cardiac disease in patients with thalassemia major: a retrospective analysis. *Haematologica*; 88:489-96.

- **Piga A, Galanello R, Forni GL, Cappellini MD, Origa R, Zappu A, Donato G, Bordone E, Lavagetto A, Zanaboni L, Sechaud R, Hewson N, Ford JM, Opitz H, Alberti D. (2006):** Randomized phase II trial of deferasirox (Exjade, ICL670), a once-daily, orally-administered iron chelator, in comparison to deferoxamine in thalassemia patients with transfusional iron overload. *Hematologica*; 91(7):873-80.

- **Platt OS, Brambilla DJ, Rosse WF, Milner PF, Castro O, Steinberg MH, Klug PP. (1994)** Mortality in sickle cell disease. Life expectancy and risk factors for early death. *N Engl J Med.*; 330: 1639–44.

- **Platt OS. .(2008):** Hydroxyurea for the treatment of sickle cell anemia. *N Engl J Med.*; 358: 1362–9.

- **Powars DR. (1991):** Beta s-gene-cluster haplotypes in sickle cell anemia. Clinical and hematologic features. *Hematol Oncol Clin North Am*; 5: 475–93.

- **Quinn CT, BuchananGR. (1999):** The acute chest syndrome of sickle cell disease. *J pediatr.* ; 135(4) : 416-22. (medline)

- **Reiter EO, Rosenfeld RG.2008,** Normal and aberrant growth. *Williams Textbook of Endocrinology*. 11th ed. Philadelphia, Pa: Saunders Elsevier;chap 23.

- **Rice HE, Oldham KT, Hillery CA, et al(2003).** Clinical and hematologic benefits of partial splenectomy for congenital hemolytic anemias in children. *Ann Surg*. Feb ;237(2):281-8.

- **Robert S. Hillman, Kenneth A. Ault, Henry M. Rinder page 136-139** Hematology in clinical practice: a guide to diagnosis and management
- **Rodgers GP. (1997):** Overview of pathophysiology and rationale for treatment of sickle cell anemia. Semin hematol. ;34(3 suppl3) : 2-7. (medline)
- **Rogers ZR. (2005):** Priapism in sickle cell disease. Hematol Oncol Clin North Am.; 19: 917–28.
- **Rund D and Rachmilewiyz EA. (2001):** Pathophysiology of α - and β - thalassemia: therapeutic implications. Semin Hematol; 38:343-9.
- **Rund D. and Rachmilewitz E. (2005):** Beta-thalassemia. N Engl J Med; 353 (11): 1135-1146
- **Rund, D. and Rachmilewitz, E. (2000):** New trends in the treatment of β -thalassemia. Crit Rev Oncol Hematol; 33:105-118.
- **Sabahattin Ocak, Hasan Kaya, Meryem Cetin, Edip Gali and Muge Ozturk(2006):** Archives of Medical Research, Volume 37, Issue 7, Pages 895-898
- **Sadelain M. (2006):** Recent advances in globin gene transfer for the treatment of beta-thalassemia and sickle cell anemia. Curr Opin Hematol.; 13: 142–8.
- **Schatz J, Brown RT, Pascual JM, Hsu L, DeBaun MR.(2001) :** Poor school and cognitive functioning with silent cerebral infarcts and sickle cell disease. Neurology.; 56: 1109–11. [PubMed]

- **Selim O, Kamel K, Sabry F, Ibrahim A, and Weatherall D.J. (1974):** Absence of the α -thalassemia syndromes in Egyptian Arabs; 11(4):335-336.
- **Serjeant GR, Higgs DR, Hambleton IR. (2007):** Elderly survivors with homozygous sickle cell disease. N Engl J Med.; 356: 642–3.
- **Serjeant GR, Serjeant BE. (2001) :** Sickle Cell Disease. 3rd Ed. Oxford University Press;.
- **Shahram Mirmomen et al (2006):** Archives of Iranian Medicine, Volume 9, Number 4,: 319 - 323.
- **Shalitin, S., Carmi, D., Weintrob, N., Phillip, M., Miskin, H., Kornreich, L., Zilber, R., Yaniv, I. and Tamary, H. (2005),** Serum ferritin level as a predictor of impaired growth and puberty in thalassemia major patients. European Journal of Haematology, 74: 93–100.
- **Skordis N, Michaelidou M, Savva SC, Ioannou Y, Rousounides A, Kleanthous M, Skordos G, Christou S. (2006)** The impact of Genotype on Endocrine complications In Thalassaemia major. Eur J Haematol. 77(2):150-6.
- **Soliman AT, elZalabany M, Amer M, Ansari BM (1999):** Growth and pubertal development in transfusion- dependent children and adolescents .
- **Spanos T, Karageorga M, Ladis V, Peristeri J, Hatziliami A, Kattamis C (1995):** Red cell alloantibodies in patients with thalassemia. Vox Sang; 58:50-55.

- **Steinberg MH, Adewoye AH. . (2006):** Modifier genes and sickle cell anemia. *Curr Opin Hematol*; 13: 131–6.
- **Steinberg MH, Barton F, Castro O, Pegelow CH, Ballas SK, Kutlar A, Orringer E, Bellevue R, Olivieri N. (2003):** Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia: risks and benefits up to 9 years of treatment. *JAMA.*; 289: 1645–51.
- **Steinberg MH. (2005):** Predicting clinical severity in sickle cell anaemia. *Br J Haematol*; 129: 465–81.
- **Stephen J. McPhee, Maxine A(2009).** Papadakis page 436 *Current Medical Diagnosis and Treatment*
- **Swirski FK, Nahrendorf M, Etzrodt M, Wildgruber M, et al (2009).** Identification of Splenic Reservoir Monocytes and Their Deployment to Inflammatory Sites. *Science*, 325: 612-616.
- **Tanner JM, Whitehouse RH, Takaishi M. (1966)** Standards from birth to maturity for height, weight, height velocity and weight velocity: British children, 1965 part II. *Arch Dis Child*; 41:613-35.
- **Toumba M, Sergis A, Kanaris C, Skordis NP(2007):** Pediatric Endocrine Unit, Department of Pediatrics, Makarios Hospital, Nicosia, Cyprus. meropitoumba@cytanet.com.cy
- **Van de Velde H, Georgiou I, De Rycke M, Schots R, Sermon K, Lissens W, Devroey P, Van Steirteghem A, Liebaers I. (2004):** Novel universal approach for preimplantation genetic diagnosis of beta-thalassaemia in combination with HLA matching of embryos. *Hum Reprod*; 19:700-8.
- **Vichinsky E. (2002):** New therapies in sickle cell disease. *Lancet.*; 360: 629–31.

- **Vichinsky EP, Neumayr LD, Earles AN, Williams R, Lennette ET, Dean D, Nickerson B, Orringer E, McKie V, Bellevue R, Daeschner C, Mancini EA. (2000):** Causes and outcomes of the acute chest syndrome in sickle cell disease. National Acute Chest Syndrome Study Group. *N Engl J Med.*; 342: 1855–65.
- **Vikram Mehta 2010** Splenectomy In Management Of Thalassemia Major - A Boon For The Little Angel.. *The Internet Journal of Surgery*. 2010 Volume 24 Number 1
- **Wahidiyat et al (1983)** *delayed puberty in thalassemic patients* *diah* 143-147.p65
- **Walters MC, Storb R, Patience M, Leisenring W, Taylor T, Sanders JE, Buchanan GE, et al., (2000):** Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Multicenter investigation of bone marrow transplantation for sickle cell disease. *Blood*; 95: 1918–24.
- **Wang FL, Boo NY, Ainoon O, et al. (2009)** Comparison of detection of glucose-6-phosphate dehydrogenase deficiency using fluorescent spot test, enzyme assay and molecular method for prediction of severe neonatal hyperbilirubinaemia. *Singapore Med J.* ;50(1):62-7.
- **Wang WC, Gallagher DM, Pegelow CH, Wright EC, Vichinsky EP, Abboud MR, Moser FG, Adams RJ. (2000):** Multicenter comparison of magnetic resonance imaging and transcranial Doppler ultrasonography in the evaluation of the central nervous system in children with sickle cell disease. *J Pediatr Hematol Oncol.*; 22: 335–9.

- **Wang WC. (2007):** The pathophysiology, prevention, and treatment of stroke in sickle cell disease. *Curr Opin Hematol.*; 14: 191–7.
- **Ware R. (2007):** Principles and indications of chronic transfusion therapy for children with sickle cell disease. *Clin Adv Hematol Oncol.*; 5: 686–8.
- **Warrell, David A.; Timothy M. Cox, John D. Firth, Edward J. Benz (2005).** *Oxford Textbook of Medicine, Volume Three.* Oxford University Press. pp. 720–725. ISBN 0-19-857013-9
- **Weatherall DJ (1999):** Genetic disorders of haemoglobin. In Hoffbrand AV, Lewis SM, Tuddenham EGD (eds) *Postgraduate Hematology* 5th ed. Butterworth- Heinemann; pp. 94-98.
- **Weatherall DJ., Clegg JB. (2001):** Historical perspective: The many and adverse routes to our current understanding of the thalassemia syndromes. 4th ed. Oxford (England): Blackwell Science; 2001 p. 3-62.
- **Weinstein DA, Roy CN, Fleming MD, Loda MF., Wolfsdorf JJ, Andrews NC (2002):** Inappropriate expression of hepcidin is associated with iron refractory anemia: Implications for the anemia of chronic disease. *Blood*; 100(10):3776-81.
- **WHO Regional Committee for Africa (2006) : 56th Annual Session Report 6-17-06.** Available at www.afro.who.int.
- **Won DI, Suh JS (March 2009).** "Flow cytometric detection of erythrocyte osmotic fragility". *Cytometry B Clin Cytom* 76 (2): 135–41. doi:10.1002/cyto.b.20448. PMID 18727072.

- **Wonke B, Hoffbrand AV, Brown D, Dusheiko G (1990)** : Antibody to hepatitis C virus in multiply transfused patients with thalassaemia major. *J Clin Pathol*;43:638-40.
- **Wood JC. (2007):** Magnetic resonance imaging measurement of iron overload. *Curr Opin Hematol.*; 14: 183–90.
- **Wright MS (1999).** "Drug-induced hemolytic anemias: increasing complications to therapeutic interventions". *Clin Lab Sci* **12** (2): 115–28.